KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2016 - 2025)

Vertex Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $55.7 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $55.7 million for Q4 2025, up 19.78% from a year ago — trailing twelve months through Dec 2025 was $209.8 million (up 1.25% YoY), and the annual figure for FY2025 was $209.8 million, up 1.25%.
  • Depreciation & Amortization (CF) for Q4 2025 was $55.7 million at Vertex Pharmaceuticals, up from $54.0 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for VRTX hit a ceiling of $59.0 million in Q4 2023 and a floor of $28.8 million in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $41.8 million (2023), compared with a mean of $43.6 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 53.65% in 2023 and later fell 21.19% in 2024.
  • Vertex Pharmaceuticals' Depreciation & Amortization (CF) stood at $33.8 million in 2021, then increased by 13.61% to $38.4 million in 2022, then surged by 53.65% to $59.0 million in 2023, then fell by 21.19% to $46.5 million in 2024, then grew by 19.78% to $55.7 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $55.7 million (Q4 2025), $54.0 million (Q3 2025), and $51.7 million (Q2 2025) per Business Quant data.